Beaudet R L, Poirier N L, Guerraty A J, Doyle D
Thorac Cardiovasc Surg. 1983 May;31 Spec 2:89-93. doi: 10.1055/s-2007-1022038.
Between 1978 and 1982, 230 consecutive patients underwent valve replacement with the Medtronic-Hall valve prosthesis. There were 95 patients with aortic valve replacement (AVR), 107 with mitral valve replacement (MVR) and 28 with aortic and mitral valve replacement (DVR). Operative mortality was 7.8%. Follow-up studies included 212 patients with a mean follow-up time of 26.5 months. Incidence of thromboembolism was 1.2%/patient year after AVR, 2.4%/patient year after MVR and 0 after DVR. Freedom from any kind of complications was 80% at 3 years. Recatheterization showed mean pressure gradients of between 0.0 and 6.0 mmHg in aortic prostheses and between 0.0 and 3.5 mmHg in mitral prostheses. It is concluded that the Medtronic-Hall valve prosthesis is a durable substitute with a low complication rate and good hemodynamic performance.
1978年至1982年间,连续230例患者接受了美敦力-霍尔瓣膜假体置换术。其中95例为主动脉瓣置换术(AVR),107例为二尖瓣置换术(MVR),28例为主动脉瓣和二尖瓣置换术(DVR)。手术死亡率为7.8%。随访研究包括212例患者,平均随访时间为26.5个月。AVR术后血栓栓塞发生率为1.2%/患者年,MVR术后为2.4%/患者年,DVR术后为0。3年时无任何并发症的生存率为80%。再次导管检查显示,主动脉假体的平均压力梯度在0.0至6.0 mmHg之间,二尖瓣假体的平均压力梯度在0.0至3.5 mmHg之间。结论是,美敦力-霍尔瓣膜假体是一种耐用的替代品,并发症发生率低,血液动力学性能良好。